710 related articles for article (PubMed ID: 18611163)
1. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis.
Chamilos G; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2008 Aug; 47(4):503-9. PubMed ID: 18611163
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
3. Forty-one recent cases of invasive zygomycosis from a global clinical registry.
Rüping MJ; Heinz WJ; Kindo AJ; Rickerts V; Lass-Flörl C; Beisel C; Herbrecht R; Roth Y; Silling G; Ullmann AJ; Borchert K; Egerer G; Maertens J; Maschmeyer G; Simon A; Wattad M; Fischer G; Vehreschild JJ; Cornely OA
J Antimicrob Chemother; 2010 Feb; 65(2):296-302. PubMed ID: 20008047
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and outcome of zygomycosis: a review of 929 reported cases.
Roden MM; Zaoutis TE; Buchanan WL; Knudsen TA; Sarkisova TA; Schaufele RL; Sein M; Sein T; Chiou CC; Chu JH; Kontoyiannis DP; Walsh TJ
Clin Infect Dis; 2005 Sep; 41(5):634-53. PubMed ID: 16080086
[TBL] [Abstract][Full Text] [Related]
5. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007.
Skiada A; Pagano L; Groll A; Zimmerli S; Dupont B; Lagrou K; Lass-Florl C; Bouza E; Klimko N; Gaustad P; Richardson M; Hamal P; Akova M; Meis JF; Rodriguez-Tudela JL; Roilides E; Mitrousia-Ziouva A; Petrikkos G;
Clin Microbiol Infect; 2011 Dec; 17(12):1859-67. PubMed ID: 21199154
[TBL] [Abstract][Full Text] [Related]
6. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection.
Nucci M; Anaissie EJ; Queiroz-Telles F; Martins CA; Trabasso P; Solza C; Mangini C; Simões BP; Colombo AL; Vaz J; Levy CE; Costa S; Moreira VA; Oliveira JS; Paraguay N; Duboc G; Voltarelli JC; Maiolino A; Pasquini R; Souza CA
Cancer; 2003 Jul; 98(2):315-9. PubMed ID: 12872351
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of cutaneous zygomycosis.
Visser DH; van den Berg YL; van Furth AM; Oomen MW; Schouten-van Meeteren AY; Pajkrt D; van den Bos C; van Well GT
Pediatr Infect Dis J; 2007 Dec; 26(12):1165-6. PubMed ID: 18043463
[TBL] [Abstract][Full Text] [Related]
8. Ten years' experience in zygomycosis at a tertiary care centre in India.
Chakrabarti A; Das A; Sharma A; Panda N; Das S; Gupta KL; Sakhuja V
J Infect; 2001 May; 42(4):261-6. PubMed ID: 11545569
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of invasive zygomycosis infections in renal transplant recipients.
Forrest GN; Mankes K
Transpl Infect Dis; 2007 Jun; 9(2):161-4. PubMed ID: 17462005
[TBL] [Abstract][Full Text] [Related]
10. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009.
Campo M; Lewis RE; Kontoyiannis DP
J Infect; 2010 May; 60(5):331-7. PubMed ID: 20138081
[TBL] [Abstract][Full Text] [Related]
11. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
Kontoyiannis DP; Lionakis MS; Lewis RE; Chamilos G; Healy M; Perego C; Safdar A; Kantarjian H; Champlin R; Walsh TJ; Raad II
J Infect Dis; 2005 Apr; 191(8):1350-60. PubMed ID: 15776383
[TBL] [Abstract][Full Text] [Related]
12. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
[TBL] [Abstract][Full Text] [Related]
13. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
14. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
Mihu CN; Kassis C; Ramos ER; Jiang Y; Hachem RY; Raad II
Cancer; 2010 Nov; 116(22):5290-6. PubMed ID: 20665889
[TBL] [Abstract][Full Text] [Related]
15. Mortality risk factors in patients with zygomycosis: a retrospective and multicentre study of 25 cases.
Llorente A; Perez-Valero I; García E; Heras I; Fraile V; García P; López J; Salavert M; Bobillo F
Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):263-8. PubMed ID: 21330008
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies.
Valentini CG; Candoni A; Fianchi L; Posteraro B; Simeone E; Costa F; Sanguinetti M; Voso MT; Caira M; Fanin R; Pagano L
Mycoses; 2010 Jan; 53(1):89-92. PubMed ID: 19207832
[TBL] [Abstract][Full Text] [Related]
17. [Invasive zygomycosis in patients treated for haematological malignancies].
Verweij PE; van der Velden WJ; Donnelly JP; Blijlevens NM; Warris A
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2597-602. PubMed ID: 18161258
[TBL] [Abstract][Full Text] [Related]
18. [Zygomycosis].
Takakura S
Nihon Rinsho; 2008 Dec; 66(12):2356-61. PubMed ID: 19069105
[TBL] [Abstract][Full Text] [Related]
19. Zygomycosis over-infection during voriconazole therapy for aspergillosis in a heart transplant patient, successfully treated with liposomal amphotericin and posaconazole.
Bourke P; Castro P; Rabagliati R; Beltran C; Verdejo H; Winter JL; Bourge RC
Transpl Infect Dis; 2012 Oct; 14(5):E56-9. PubMed ID: 22852999
[TBL] [Abstract][Full Text] [Related]
20. Favourable outcome of pulmonary zygomycosis in haematological malignancy.
Opeskin K; Sheorey H; Wright G; Nandurkar H
Pathology; 2006 Jun; 38(3):271-3. PubMed ID: 16753758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
